<div id="readability-page-1"><div><p>China's Supreme People's Court has upheld the validity of the substance patent for semaglutide, thereby confirming a previous ruling from the Beijing IP Court.</p><p>  The decision strengthens Novo Nordisk's intellectual property rights in the world's second-largest economy. </p><p>  &#34;This outcome is very positive for semaglutide and demonstrates strong government support for protecting medical innovation,&#34; said Mike Doustdar, CEO of Novo Nordisk. </p><p>  &#34;The decision also boosts confidence in the sustainable development of foreign companies in China and will encourage further development and introduction of innovative medicines for the benefit of patients.&#34; </p><p>The company stated that the ruling does not change previous communications regarding patent expirations or forecasts. No financial details were disclosed.</p></div></div>

诺和诺德公司

<p>中国最高人民法院维持了诺和诺德公司的赛美特（semaglutide）专利，强化了该公司的知识产权。首席执行官 Mike Doustdar 表示，这一裁决支持了医疗创新，并增强了外国公司在中国的信心，鼓励创新药物的发展。该裁决并未改变之前关于专利到期或预测的沟通，也没有提供财务细节</p>

中国法院维持了诺和诺德公司的专利权